 Jeffrey T. Yap, PH.D.
| Title | Assistant Professor of Radiology |
|---|
| Institution | Dana-Farber Cancer Institute |
|---|
| Department | Radiology |
|---|
| Address | Dana Farber Cancer Institute
Division of Nuclear Medicine
44 Binney St
Boston MA 02115
|
|---|
|
|
|
 Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 1; 30(19):2401-7.
-
Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74.
-
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
-
Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen AB. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiother Oncol. 2012 Mar; 102(3):377-82.
-
Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):e99-105.
-
Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
-
Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
-
Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco RI. Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions. Int J Radiat Oncol Biol Phys. 2011 Jul 1; 80(3):900-8.
-
Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
-
Balter JM, Haffty BG, Dunnick NR, Siegel EL. Imaging opportunities in radiation oncology. Int J Radiat Oncol Biol Phys. 2011 Feb 1; 79(2):342-7.
-
Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol. 2009 Aug; 193(2):326-32.
-
George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 1; 27(19):3154-60.
-
Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009 Mar 15; 15(6):1891-7.
-
Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
-
Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Syngal S, Garber JE. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9.
-
Wall JS, Kennel SJ, Paulus M, Gregor J, Richey T, Avenell J, Yap J, Townsend D, Weiss DT, Solomon A. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med. 2006 Dec; 47(12):2016-24.
-
Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun; 47(6):1059-66.
-
Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J. 2004 Jul-Aug; 10(4):221-33.
-
Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med. 2004 Jan; 45 Suppl 1:4S-14S.
-
Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003 Jul 21; 89(2):262-7.
-
Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003 Aug 1; 21(15):2823-30.
-
Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet. 2000 Jun 17; 355(9221):2125-31.
-
Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham VJ. On-line measurement of exhaled [11C]CO2 during PET. J Nucl Med. 2000 Apr; 41(4):605-11.
-
Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ. A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med. 2000 Apr; 41(4):706-11.
-
Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med. 1999 Nov; 40(11):1848-56.
-
Kao CM, Yap JT, Mukherjee J, Wernick MN. Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram. IEEE Trans Med Imaging. 1997 Dec; 16(6):738-49.
This graph shows the total number of publications by year.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
|
Yap's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|